Glycorex Transplantation AB Class B
NNGM:GTAB.B1.60
SEK
+0.07
(+4.23%)
Glycorex Transplantation AB Class B
NGM:GTAB.B
(Nordic Growth Market)
Recent
price
1.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Glycorex Transplantation AB is a Sweden-based medical technology company that specializes in the development, manufacturing, and commercialization of advanced medical devices and biomaterials for extracorporeal blood purification, antigen-specific immunoadsorption, and apheresis. Founded in 1996 and headquartered in Lund, Sweden, the company is listed on the Nordic Growth Market under the ticker symbol GTAB B. Glycorex Transplantation AB operates in the healthcare and life sciences sector, providing proprietary therapeutic solutions to university hospitals, organ transplant centers, transfusion medicine clinics, and blood banks across more than 30 countries in Europe, Asia, Latin America, and Africa. The company core product and service portfolio encompasses: Glycosorb ABO, a proprietary medical device utilizing synthetic carbohydrate antigens to selectively eliminate anti-A and anti-B antibodies from patient plasma, enabling ABO-incompatible living and deceased donor kidney, liver, heart, lung, and stem cell transplantations while mitigating the risk of antibody-mediated rejection; universal blood plasma and transfusion preparation devices designed for the depletion of anti-A and anti-B isoagglutinins from donor blood products to enhance the safety and availability of plasma and platelet transfusions; therapeutic apheresis columns under development for autoimmune diseases, targeting the selective removal of pathogenic autoantibodies in indications such as rheumatoid arthritis and myasthenia gravis; and customized bioseparation matrices and carbohydrate chemistry research services focused on galectin-binding molecules for inflammatory disorders. In recent operational and strategic developments, Glycorex Transplantation AB has significantly broadened its international commercial footprint through strategic distribution partnerships, including an agreement with Grupo VIDA to distribute Glycosorb ABO in Brazil, a distribution alliance with OneMedik (M) SDN BHD for the Malaysian market, and commercial agreements in Greece and Argentina spanning transplantation and transfusion applications. The company has also achieved key geographic clinical milestones, facilitating the first ABO-incompatible transplantations using its Glycosorb ABO technology in Morocco, Portugal, Mexico, and Argentina, as well as the first blood-group-incompatible pediatric heart transplantation in Austria. Additionally, Glycorex Transplantation AB continues to advance its clinical validation and regulatory compliance efforts, including presenting pediatric transplantation findings published in the Journal of Heart and Lung Transplantation, demonstrating clinical efficacy in platelet transfusion evaluations, and transitioning its product portfolio under the European Union Medical Device Regulation framework.